Last updated: May 27, 2026
PRIALT (ziconotide) suppliers: Who manufactures, supplies, and controls PRIALT supply for intrathecal use?
Executive summary: PRIALT (ziconotide) is supplied as a branded intrathecal product by Bayer in the US, with delivery-system and process supply tied to Bayer’s manufacturing network. Patent and exclusivity are not the gating factor for procurement; the gating factor is single-brand market structure and limited manufacturing qualification for intrathecal products.
Because this request is strictly about “suppliers,” the supplier set below is limited to commercial product suppliers and distribution-control entities tied to PRIALT in regulated channels, not speculative raw-material sources.
Who supplies PRIALT (ziconotide) to US hospitals and wholesalers?
Direct answer: Bayer supplies PRIALT to the US channel through its commercial organization and contracted distribution partners for prescription drug distribution.
What does “supplier” mean in PRIALT procurement?
In hospital pharmacy practice, “supplier” typically maps to:
- Labeler / NDA holder (commercial responsibility and distribution oversight)
- Wholesale distribution channel (who hospitals buy from)
- Manufacturer-of-record (who releases lots under cGMP)
- Contract manufacturing or packaging partners (who performs steps under Bayer quality systems)
For PRIALT, the relevant supplier identity at the procurement layer is Bayer as the product brand’s commercial sponsor.
What companies manufacture PRIALT (ziconotide) under Bayer’s label?
Direct answer: PRIALT is manufactured under Bayer’s control as the holder of the branded product in the marketed market.
Key manufacturing responsibility lines
- Bayer: product quality system ownership, release responsibility under the marketed product registration framework
- Manufacturer of record for finished dose: the specific site(s) that perform final manufacture and lot release (varies by market and time)
Is there a second source for PRIALT production or only one branded supplier?
Direct answer: PRIALT is not a multi-source generic product in the way most small-molecule injectable CNS drugs are. Market structure has supported single-brand supply rather than multiple interchangeable finished-dose sources.
Procurement impact
- Hospitals typically buy from wholesale distributors carrying the branded product.
- Replacement sourcing usually means channel redistribution, not swapping to an approved alternative finished-dose product at the same time.
What raw-material or component suppliers support ziconotide intrathecal products?
Direct answer: Specific component suppliers for ziconotide API, formulation excipients, and intrathecal packaging are typically vendor-managed through NDA holder qualification and do not publish as a stable public list in the way finished-dose suppliers do.
Why component vendor lists are rarely public
- Suppliers change across qualification cycles
- Qualified vendor lists are controlled under quality agreements
- Intrathecal product systems and sterilization/packaging controls restrict switching
What is the distribution chain for PRIALT (ziconotide) in the US?
Direct answer: PRIALT is distributed through the US wholesale channel from the branded supplier (Bayer) to wholesalers and then to hospitals and specialty pharmacies.
Typical chain-of-custody endpoints
- Wholesaler: inventory holding and order fulfillment
- Hospital inpatient pharmacy or specialty distributor: stocking and administration logistics
- Clinician: intrathecal administration under REMS-style clinical oversight if applicable (PRIALT has administration constraints tied to intrathecal use)
What patent or regulatory issues restrict PRIALT supplier switching?
Direct answer: PRIALT supplier switching is more constrained by product availability and manufacturing qualification than by buyer-side patent restrictions.
Why patents matter less for “suppliers”
Patents affect generic or competitor entry, but the day-to-day procurement question (“Who can supply me this product?”) is answered by:
- approved finished-dose listings
- lot-release capability
- distributor stocking
How do FDA approvals affect which suppliers can sell PRIALT?
Direct answer: Only suppliers tied to FDA-approved finished-dose marketing and qualified manufacturing can sell PRIALT in the regulated channel.
What FDA regulates that affects supply
- NDA/labeling permissions for manufacturing changes
- cGMP release
- stability and packaging system integrity for intrathecal administration
PRIALT supplier landscape: Bayer vs. alternative products
Direct answer: There is no “direct PRIALT interchangeable” supplier category equivalent to generic competition for a typical small-molecule injectable.
Substitution risk in practice
Hospitals that cannot source PRIALT often pivot to:
- alternative intrathecal analgesic strategies
- other chronic pain agents under clinical guidance
That is a therapy substitution question, not a PRIALT supplier swap.
Key Takeaways
- Bayer is the core commercial supplier identity for PRIALT in the US channel.
- Finished-dose supply is brand-structure driven, with limited direct interchangeable sourcing.
- Component and API vendor lists are generally not publicly stable; procurement typically operates through Bayer label-controlled manufacturing and qualified supply chains.
- Supplier-switch decisions are constrained by FDA-qualified finished-dose manufacturing, lot release, and intrathecal product quality systems.
FAQs
- Who is the labeler for PRIALT (ziconotide)?
- Can hospitals substitute another supplier if PRIALT backorders occur?
- Are there any approved generic versions of PRIALT in the US?
- What distributors typically carry PRIALT for hospital procurement?
- Do API or excipient supplier changes require FDA notification for PRIALT?
References (APA)
- FDA. (n.d.). Drugs@FDA: PRIALT (ziconotide). U.S. Food and Drug Administration.
- Orange Book: Center for Drug Evaluation and Research. (n.d.). Therapeutic equivalence evaluations for ziconotide products (PRIALT entries). U.S. Food and Drug Administration.
